IMUX
Immunic Inc
10.60$
+2.6%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -17.6% | -28.1% | -5.7% | -75.2% | +340.3% | +154.5% | -17.1% | -8.2% | -57.5% | -24.7% | -41.1% | |
| – | -18.8% | -27.8% | -5.4% | -75.5% | +126.5% | +315.0% | -21.5% | +19.9% | -58.3% | -25.1% | -41.9% | |
| – | -18.4% | -28.1% | -5.2% | -76.6% | +120.4% | +334.0% | -31.8% | +22.9% | -56.3% | -23.6% | -56.6% | |
| – | -18.4% | -28.1% | -5.2% | -76.6% | +120.4% | +334.0% | -31.8% | +34.0% | -59.9% | -23.6% | -56.6% | |
| – | – | – | – | – | +113.6% | -27.7% | +628.8% | -86.2% | +137.5% | -2.7% | +502.6% | |
| – | – | – | – | – | – | – | -162.9% | – | – | – | – | |
| – | +24.2% | -34.2% | -14.0% | -67.1% | -88.7% | +153.8% | +441.9% | -73.3% | – | – | – | |
| – | – | – | – | – | – | +0.0% | +0.0% | -100.0% | – | – | – | |
| – | – | – | -11.4% | – | – | +0.0% | +0.0% | – | – | – | – | |
| – | -35.8% | -17.4% | +85.3% | -75.3% | +197.6% | +19.5% | +32.1% | +17.4% | +80.3% | -11.5% | +36.9% | |
| – | -35.3% | -17.7% | +87.6% | -75.6% | +181.8% | +18.7% | +35.8% | +14.7% | +89.1% | -10.3% | +38.1% | |
| – | – | – | – | – | – | -91.0% | +37.4% | +40.0% | +21.7% | +6.5% | -36.5% | |
| – | +5.9% | -36.1% | +34.5% | -74.5% | +804.1% | +52.7% | -5.4% | +22.3% | +19.1% | +53.9% | +29.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -15.6% | -29.0% | -14.4% | -75.2% | +369.6% | +172.1% | -19.9% | -10.6% | -74.6% | -36.3% | -136.2% | |
| – | -307.9% | – | – | – | – | – | – | – | – | – | – | |
| – | +56.7% | +24.8% | +27.0% | -15.0% | +811.8% | +102.8% | +51.0% | +34.5% | +39.3% | +126.0% | +55.4% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.